V
enous thromboembolism (VTE) is an important cause of illness in elective total hip replacement (THR) and total knee replacement (TKR), which are increasingly performed in aging populations. A recent analysis incorporating data from trials and observational studies estimated the contemporary 35-day rate of symptomatic VTE without thromboprophylaxis at 4.3% (1) .
These procedures may also be associated with an increased risk for major bleeding, estimated to occur in 1.5% of patients having THR or TKR without thromboprophylaxis (1) . Bleeding can be associated with infections, reoperation, delayed wound healing, and extended hospital stay (2) . Pharmacologic thromboprophylaxis for THR or TKR decreases VTE by approximately 50% but causes increased bleeding (3) . The choice of antithrombotic thus involves a pivotal balance between the risks for VTE and bleeding.
Current guidelines recommend thromboprophylaxis in patients having THR or TKR (1, 4, 5) . The most commonly used anticoagulants are low-molecular-weight heparin (LMWH), fondaparinux, and adjusted-dose warfarin (6 -8) . Other options include unfractionated heparin, aspirin, mechanical prophylaxis, and new oral anticoagulants (NOACs).
The efficacy and safety of LMWH have been wellestablished (3, 5, 9) . It has a long half-life, allowing a once-daily dosing schedule and good bioavailability. Disadvantages include parenteral administration, suboptimum patient adherence (10) , expense, and potential thrombocytopenia (11) . Fondaparinux, an injectable factor Xa inhibitor, also has good bioavailability (12) . Warfarin is inexpensive and is administered orally once daily but requires regular monitoring and has many interactions with drugs, herbs, and dietary products (13) .
Oral factor Xa inhibitors and direct thrombin inhibitors (DTIs) have more predictable anticoagulant effects, eliminating the need for monitoring in short-term thromboprophylaxis. Disadvantages of NOACs include costs and the lack of antidotes for timely reversal in case of bleeding. Rivaroxaban, an oral factor Xa inhibitor, is approved by the U.S. Food and Drug Administration (FDA) for thromboprophylaxis in orthopedic surgery. Other oral factor Xa inhibitors that are FDA-approved for other indications or are under development include edoxaban and betrixaban. Dabigatran etexilate is an oral DTI with a better drug interaction profile than warfarin (14) and is under review by the FDA for surgical thromboprophylaxis.
The U.S. Department of Veterans Affairs commissioned this review to assess the comparative effectiveness of NOACs and standard thromboprophylaxis regimens in THR and TKR.
METHODS
We followed a standard protocol for all steps of this review. A technical report with details of our methods and results for all 3 original key research questions (2 are addressed in this article) is available at www.hsrd.research.va .gov/publications/esp.
Key Questions
In relation to the incidence of symptomatic, objectively confirmed VTE, other VTE events, total mortality, and bleeding outcomes for THR or TKR patients, what is the comparative effectiveness of NOACs and standard thromboprophylactic drug classes (key question 1) , and what is the comparative efficacy of individual NOACs (key question 2)?
Data Sources and Searches
We identified many high-quality, recent systematic reviews that addressed our key questions and concluded that a synthesis of these reviews would effectively summarize the evidence. In collaboration with a master librarian, we searched MEDLINE (via PubMed), EMBASE, and the Cochrane Database of Systematic Reviews for systematic reviews comparing NOACs with other types of thromboprophylaxis from January 2009 through March 2013. We used the National Library of Medicine's Medical Subject Headings keyword nomenclature and text words for NOACs, the conditions of interest, and validated search terms for systematic reviews (15, 16) (Appendix Table 1 , available at www.annals.org).
We also manually searched citations from reviews and clinical guidelines (1, (17) (18) (19) (20) (21) . A primary literature search identified no eligible randomized, controlled trials published after the included reviews.
Study Selection, Data Extraction, and Quality Assessment
Two reviewers used prespecified eligibility criteria to assess all titles and abstracts (Appendix Table 2 , available at www.annals.org), and 2 different reviewers retrieved potentially eligible full-text reviews for further evaluation. Disagreements on inclusion or exclusion were resolved by discussion or a third reviewer. Appendix Table 3 (available at www.annals.org) lists articles excluded at full-text review.
Abstraction and quality assessment were performed by 1 reviewer and confirmed by a second. Appendix Table 4 (available at www.annals.org) summarizes key quality criteria, adapted from the Assessment of Multiple Systematic Reviews and QUOROM (Quality of Reporting of Metaanalyses) criteria (22) (23) (24) . We added supplemental criteria for studies that used multiple treatment comparisons and considered the similarity among trials for moderators of relative treatment effect (25) and the consistency of results between direct and indirect comparisons (26) . Reviews were categorized as good, fair, or poor quality. Poor-quality reviews were excluded. Disagreements were resolved by a third reviewer.
Data Synthesis and Analysis
We analyzed and summarized the results from each included review and produced summary tables for comparison across reviews. We focused on results from higherquality reviews with more complete drug comparisons (for example, by drug class rather than drug only) and more detailed information about population, intervention, and outcome definitions. In addition to summary measures of relative effects (for example, risk ratios [RRs]), we reported absolute risk differences in the summary strength-ofevidence (SOE) tables ( Table 1 and Appendix Table 5 , available at www.annals.org).
To standardize reporting, we estimated the absolute treatment effect by calculating the risk difference, using relative risks from meta-analyses with baseline risk estimates (27) . Using pooled data from trials and a large cohort study, Neumann and colleagues (20) estimated baseline risk among patients treated with LMWH, the common comparator for NOACs, for each major outcome: symptomatic deep venous thrombosis (DVT) (9 events per 1000 patients), nonfatal pulmonary embolism (PE) (3 per 1000 patients), death (3 per 1000 patients), and major bleeding (7 per 1000 patients). After summarizing the prioritized reviews, we compared each additional review that addressed the same question. If findings differed importantly across reviews, we analyzed potential reasons for discrepancies, such as the primary literature included, inclusion or exclusion criteria, outcome definitions, analytic approach, and conflicts of interest.
We followed the approach recommended by the Agency for Healthcare Research and Quality to evaluate the overall quality of evidence (28), assessing 4 domains: risk of bias, consistency, directness, and precision. For risk of bias, we used quality assessment of study design for the primary literature reported in the reviews. We used results from meta-analyses when evaluating consistency (forest plots and tests for heterogeneity), precision (CIs), strength of association (odds ratios), and whether publication bias was detected (funnel plots or the Begg test). An SOE rating of high, moderate, low, or insufficient was assigned after discussion by 2 reviewers (29).
RESULTS
Our electronic and manual searches identified 182 unique citations. Of these, 6 recent, good-quality systematic reviews (3, 17, 19 -21, 30) , grouped by relevance to key question, were included in the evidence report (31) (Figure 1 ). All identified reviews directly compared NOACs with other types of thromboprophylaxis used in THR or TKR (key question 1), although 1 review considered only safety outcomes, such as major bleeding (30) . Two reviews compared 1 NOAC with another (key question 2), but comparisons were indirect through enoxaparin (17, 19) . Search dates of systematic reviews ranged from May 2009 to December 2011; most searches included MEDLINE and the Cochrane Library. Table 2 summarizes the characteristics of the reviews. Appendix Table 4 presents detailed quality assessments. Table 6 (available at www.annals.org) shows the overlap of included studies across reviews.
Appendix
All reviews assessed the included trials as good quality. The most common problems were unclear allocation concealment and incomplete reporting of outcome data. Publication bias was usually evaluated with funnel plots, which did not indicate bias favoring NOACs. All studies conducted random-effects meta-analyses, but specific strategies varied.
Two reviews compared drug classes (for example, factor Xa inhibitors vs. LMWH) (3, 20) , whereas the other 4 compared individual drugs, some analyzing studies of THR and TKR separately. All of the reviews used direct comparisons; 2 also provided indirect comparisons (17, 19) . All but 1 review (19) evaluated major bleeding by using the same standard definition (1). DVT ϭ deep venous thrombosis; DTI ϭ direct thrombin inhibitor; FXa ϭ factor Xa; LMWH ϭ low-molecular-weight heparin; NA ϭ not applicable; NOACs ϭ newer oral anticoagulants; OR ϭ odds ratio; PE ϭ pulmonary embolism; RCT ϭ randomized, controlled trial; RD ϭ risk difference; RR ϭ risk ratio; SOE ϭ strength of evidence; THR ϭ total hip replacement; TKR ϭ total knee replacement. * Outcomes are short-term; there may be some differences for THR vs. TKR (different baseline risk and duration of anticoagulation in existing studies); and some evidence suggests that FXa inhibitors at higher doses increase risk for bleeding. † Data obtained from reference 20. ‡ RR data obtained from references 17 and 21; RD calculated; SOE ratings obtained from reference 3.
Our other prespecified primary outcomes-all-cause mortality, symptomatic DVT, and nonfatal PE-were reported in 3 reviews (3, 20, 21) . Comparing results from the other reviews (17, 19, 30) was difficult because of differences in their outcome definitions, many of which were composite outcomes. For example, 1 review (19) defined the composite primary outcome as "total VTE," which included "DVT, non-fatal PE and all-cause mortality."
Information on the populations studied was limited in all of the reviews ( Table 3) . Risk factors for VTE were limited to a history of VTE (2 reviews) or cancer (1 review). No other risk profiles or population characteristics were reported.
Effects of Oral Factor Xa Inhibitors Compared With LMWH
All 6 systematic reviews (3, 17, 19 -21, 30 ) evaluated thromboprophylaxis using NOACs versus LMWH. For each comparison, we focused on the review with the most recent search date, the most comprehensive analysis, and our prespecified outcomes of interest. Other reviews are described briefly when findings differed importantly or additional analyses provided relevant results.
Neumann and colleagues (20) included 22 randomized, controlled trials (32 159 patients) and compared oral factor Xa inhibitors with LMWH for surgical thromboprophylaxis. Factor Xa inhibitors included apixaban (4 studies); rivaroxaban (8 studies); edoxaban (4 studies); YM150 (2 studies); and LY1517717, TAK442, razaxaban, and betrixaban (1 study each) ( Table 2) . Of these, rivaroxaban and apixaban are available in the United States.
In most trials, the European-approved dosage of enoxaparin (40 mg daily) was the comparator instead of the U.S.-approved dosage (30 mg twice daily). Rivaroxaban thromboprophylaxis was started 6 hours after surgery in most studies, whereas apixaban was started 12 to 24 hours after surgery. The duration of thromboprophylaxis was 14 days or fewer in all but 4 trials. In addition to a random-effects meta-analysis of drug class comparisons, Neumann and colleagues performed a meta-analysis comparing multiple treatments to evaluate dose effects and sensitivity analyses to examine the effects of missing outcomes. Pooled estimates of effect were presented as summary odds ratios and risk differences.
Neumann and colleagues found high SOE ( Table 1 ) suggesting no important difference between oral factor Xa inhibitors as a drug class and LMWH for all-cause mortality and nonfatal PE in patients having THR or TKR (20) (Figure 2) . However, high SOE indicated that the risk for symptomatic DVT is decreased by 4 events per 1000 patients with factor Xa inhibitors compared with LMWH.
In the same comparison, moderate SOE (because of inconsistency) suggested that the risk for major bleeding may be increased with factor Xa inhibitors. This represents an increase of 2 major bleeding events per 1000 patients. The pooled effect estimate of bleeding that led to reoperation also increased (odds ratio, 1.62 [95% CI, 0.82 to 3.19]; I 2 ϭ 1%) but with a wide CI. In a subgroup analysis, higher, but not intermediate or lower, doses of factor Xa inhibitors were associated with increased risk for bleeding (odds ratio, 2.50 [CI, 1.38 to 4.53]; P ϭ 0.02). Although the authors did not give dose ranges for these categories, total daily dosages ranged from 5 to 20 mg for apixaban and 5 to 60 mg for rivaroxaban in the primary studies. Sensitivity analyses did not differ appreciably from the main analyses.
Neumann and colleagues (20) concluded that there is no important difference between low-dose oral factor Xa inhibitors and LMWH for all-cause mortality, nonfatal PE, and major bleeding, but there is a small reduction in symptomatic DVT with factor Xa inhibitors. Limitations of trials included in the review were reporting bleeding as a composite outcome, missing outcomes for 3% to 41% of patients, short duration of treatment and follow-up, and enoxaparin dosing that was not the U.S. standard.
The other systematic reviews evaluating factor Xa inhibitors (3, 17, 19, 21, 30) generally agreed with Neumann and colleagues' findings but offered additional analyses and outcomes. Disagreements were mainly from differences in outcome definitions and approaches to data analysis and fewer included studies due to earlier search dates or more restrictive inclusion criteria.
Notable Findings From the Other Systematic Reviews
In a review (17) (17) . Three studies used a 3-group design; the 150-mg and 220-mg dabigatran groups were combined for metaanalysis. The 2-group trial evaluated only dabigatran, 220 mg, a dose not approved by the FDA.
In a random-effects meta-analysis, the risk for symptomatic PE and DVT did not differ between dabigatran and enoxaparin (17) (Figure 2) . In a similar manner, no significant difference occurred in symptomatic VTE, but treatment effects differed substantially across studies (I 2 ϭ 73%). Major bleeding events did not differ with dabigatran. In subgroup analyses, no significant interaction occurred between type of surgery or dabigatran dose and effects on symptomatic VTE or clinically relevant bleeding.
Additional Outcomes Reported by Other Systematic Reviews
Ringerike and colleagues (21) included an additional study (BISTRO-II [phase 2 of the Boehringer Ingelheim Study in Thrombosis]) (32) , but anticoagulation was received for only 7 days. Sobieraj and associates (3) evaluated an injectable DTI (desirudin) but did not include the most recent trial of an oral DTI (32) , which Loe and coworkers (19) also omitted. Mortality rates did not differ significantly for DTIs versus enoxaparin in these analyses.
Major bleeding did not differ among drug classes when analyzed by surgery type (21) or in aggregate (3, 19) , which was consistent with Gómez-Outes and colleagues' findings (17) . Sobieraj and associates (3) found no significant difference between LMWH and dabigatran for bleeding leading to rehospitalization (RR, 1.27 [CI, 0.43 to 3.75]; moderate SOE), although CIs were wide.
Effects of Individual NOACs
In the absence of direct comparisons among NOACs, 2 good-quality systematic reviews used indirect comparisons to analyze these drugs (17, 19) . Gómez-Outes and colleagues (17) evaluated apixaban (4 trials), dabigatran (4 trials), and rivaroxaban (8 trials) against a common comparator, enoxaparin. These indirect comparisons used pooled RRs and yielded an unbiased estimate of effect "when there is no interaction between covariates defining subgroups of patients (reflected, for instance, in different inclusion criteria in different studies) and the magnitude of the treatment effect" (33) . Of the 16 trials (n ϭ 38 747), 8 involved THR and 8 involved TKR.
Outcomes reported in the indirect comparisons included symptomatic VTE (DVT or PE), clinically relevant bleeding, major bleeding, and a net clinical end point (the composite of symptomatic VTE, major bleeding, and allcause mortality). The primary trials were rated as having low risk of bias. Individual drug comparisons across these 4 outcomes (12 comparisons) showed only 1 significant difference: Rivaroxaban resulted in more clinically relevant bleeding events than apixaban (RR, 1.52 [CI, 1.19 to 1.95]).
Risk for major bleeding was also increased with rivaroxaban compared with apixaban (RR, 1.59 [CI, 0.84 to 33] ), but neither comparison was significant. Overall, decreased VTE events seemed to be offset by increased major bleeding episodes, with no obvious difference on the net clinical end point among apixaban, dabigatran, and rivaroxaban. Gómez-Outes and colleagues concluded that "higher efficacy of new anticoagulants was generally associated with higher bleeding tendency. The new anticoagulants did not differ significantly for efficacy and safety" (17) . Loke and coworkers (19) used indirect analysis but excluded studies of apixaban, yielding a less informative analysis. In addition, they excluded a dabigatran trial published after 2009 and 3 rivaroxaban studies because of more restrictive eligibility criteria. Despite these differences, findings about rivaroxaban compared with dabigatran were generally similar.
The authors concluded that rivaroxaban was superior to dabigatran in preventing VTE (RR, 0.50 [CI, 0.37 to 0.68]) but with an increased risk for bleeding (RR, 1.14 [CI, 0.80 to 1.64]). These findings were consistent across different doses of dabigatran (150 mg vs. 220 mg), different dosages of enoxaparin in the control groups (30 mg twice daily vs. 40 mg once daily), and surgery type (THR vs. TKR).
DISCUSSION
Our metasynthesis identified 6 good-quality systematic reviews that evaluated thromboprophylaxis using NOACs versus LMWH. During the peer-review process, we updated our search to March 2013 and identified 1 additional eligible review comparing apixaban with enoxaparin (34) . The review did not include additional primary studies or novel findings. Although we identified no direct comparisons of NOACs, 2 good-quality reviews indirectly evaluated 1 NOAC with another by common comparison with enoxaparin (17, 19) . Compared with LMWH (typically enoxaparin, 40 mg daily), NOACs showed similar effects on most major clinical outcomes; however, the SOE varied by drug class and specific drug.
Factor Xa inhibitors have been studied more extensively than DTIs. The risk for symptomatic DVT was reduced with factor Xa inhibitors compared with LMWH (high SOE), whereas the risk for nonfatal PE and death was not significantly different (high SOE). These benefits were offset by an increase in major bleeding (moderate SOE). Compared with LMWH, dabigatran did not significantly differ for any outcome examined (low to moderate SOE).
Two reviews indirectly compared rivaroxaban, apixaban, and dabigatran through common comparison with LMWH (17, 30) . Rivaroxaban was associated with an increased risk for clinically relevant bleeding, but there was no obvious difference in net clinical end points (symptomatic VTE, major bleeding, and death). In the absence of head-to-head comparisons among NOACs, conclusions about differences among individual NOACs were uncertain.
The American College of Chest Physicians recommends antithrombotic prophylaxis over no prophylaxis for patients having THR or TKR (1) . The guidelines consider any of the following strategies to be better than no thromboprophylaxis: LMWH, fondaparinux, apixaban, dabigatran, rivaroxaban, low-dose unfractionated heparin, adjusteddose warfarin, aspirin, or an intermittent pneumatic compression device. However, in the absence of increased bleeding risk, LMWH is preferred over other agents. Factors identified as increasing risk for bleeding include previous major bleeding events, severe renal failure, concomitant antiplatelet use, and difficult-to-control bleeding during the current surgery (1) .
For patients with increased risk for bleeding, the American College of Chest Physicians recommends an intermittent pneumatic compression device or no prophylaxis. In contrast, the American Academy of Orthopaedic Surgeons (18) suggests individual assessment of patients for thromboprophylaxis. For patients at average risk, the guidelines do not recommend a specific thromboprophylactic strategy and consider the evidence for comparative effectiveness to be inconclusive.
Our findings echo the recommendations of the American College of Chest Physicians and American Academy of Orthopaedic Surgeons ( Table 4) . Careful assessment of the individual risk for bleeding can dictate the choice of thromboprophylaxis. Compared with LMWH, factor Xa inhibitors at higher doses were associated with increased Current evidence is unclear about which prophylactic strategy is optimal or suboptimal. Therefore, we are unable to recommend for or against specific prophylactics in these patients. Grade: Inconclusive
In patients undergoing major orthopedic surgery, we suggest using dual prophylaxis with an antithrombotic agent and an IPCD during the hospital stay (Grade 2C).
In the absence of reliable evidence, patients who have had a previous VTE should receive pharmacologic prophylaxis and mechanical compressive devices. Grade: Consensus In patients undergoing major orthopedic surgery and increased risk of bleeding, we suggest using an IPCD or no prophylaxis rather than pharmacologic treatment (Grade 2C).
In the absence of reliable evidence, patients with a known bleeding disorder and/or active liver disease should use mechanical compressive devices for preventing VTE. Grade: Consensus In patients undergoing major orthopedic surgery and who decline or are uncooperative with injections or an IPCD, we recommend using apixaban or dabigatran (alternatively, rivaroxaban or adjusted-dose VKA if apixaban or dabigatran are unavailable) rather than other forms of prophylaxis (Grade 1B).
In the absence of reliable evidence about how long to employ these prophylactic strategies, it is the opinion of this work group that patients discuss the duration of prophylaxis with their treating physicians. Grade: Consensus ACCP ϭ American College of Chest Physicians; AAOS ϭ American Academy of Orthopaedic Surgeons; LMWH ϭ low-molecular-weight heparin; RCT ϭ randomized, controlled trial; THR ϭ total hip replacement; TKR ϭ total knee replacement; VKA ϭ vitamin K antagonist; VTE ϭ venous thromboembolism. * Grade 1 recommendations are strong and indicate that the benefits do or do not outweigh risks, burden, and costs, whereas Grade 2 suggestions imply that individual patient values may lead to different choices. Furthermore, level A indicates consistent results from RCTs or observational studies with very strong association and secure generalization (high), B indicates inconsistent results from RCTs or RCTs with methodological limitations (moderate), C indicates unbiased observational studies (low), and D indicates other observational studies (e.g., case series) (very low).
† Grading was as follows: strong when good-quality evidence, moderate when fair-quality evidence, weak when poor-quality evidence, inconclusive when insufficient or conflicting evidence, or consensus in the absence of reliable evidence.
risk for major bleeding despite reducing the risk for symptomatic DVT. Further, indirect comparison of individual NOACs showed that rivaroxaban was associated with increased risk for clinically relevant bleeding compared with apixaban and dabigatran. The differential effect of NOACs on the risk for bleeding could be related to the timing of thromboprophylaxis. Rivaroxaban thromboprophylaxis was typically started earlier than apixaban, which may increase the risk for bleeding. Patients may prefer NOACs over standard thromboprophylactic agents to avoid parenteral administration or laboratory monitoring. However, the effectiveness of NOACs in standard clinical practice may differ from our findings if the strict eligibility criteria used in the clinical trials are not followed in routine care. Thus, although evidence shows that NOACs are noninferior to LMWH for thromboprophylaxis, the real risk profile of NOACs in clinical practice will be further defined as experience is accrued with these drugs.
Our study has many strengths, including a protocoldriven review, a comprehensive search, and careful quality assessment. Another strength is the opportunity for metasynthesis from existing systematic reviews and for carefully evaluating the reasons for different findings or conclusions across published reviews. Our study limitations include comparisons of NOACs with different doses of LMWH (35) and the lack of head-to-head comparisons of NOACs, which precludes strong conclusions on their comparative effectiveness. Further, the duration of experience with these drugs is too short to allow identification of longerterm adverse events that may emerge with more widespread use.
For THR or TKR, the 35-day rate of symptomatic VTE without thromboprophylaxis is estimated to be 4.3%. Pharmacologic thromboprophylaxis decreases VTE by approximately 50% but with the tradeoff of increased bleeding. Compared with LMWH, oral factor Xa inhibitors are associated with a reduced risk for symptomatic DVT; however, death and nonfatal PE are not significantly different and the risk for major bleeding is increased.
Indirect comparisons suggest only small differences among NOACs. Longer clinical experience and direct drug-to-drug comparisons are needed to better assess the risk-benefit ratio of NOACs for surgical thromboprophylaxis. On the basis of current evidence, NOACs-particularly factor Xa inhibitors-are reasonable options for thromboprophylaxis in THR or TKR patients, although they should be used with caution in patients at increased risk for bleeding.
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